A pilot replication of QUIT, a randomized controlled trial of a brief intervention for reducing risky drug use, among Latino primary care patients. (1st October 2017)

• Record Type: Journal Article
• Authors: Gelberg, Lillian; Andersen, Ronald M.; Rico, Melvin W.; Vahidi, Mani; Natera Rey, Guillermina; Shoptaw, Steve; Leake, Barbara D.; Serota, Martin; Singleton, Kyle; Baumeister, Sebastian E.
• Is Part Of: Drug and alcohol dependence. Volume 179(2017)
• Page Start: 433
• Page End: 440
• Publication Date: 2017-10-01
• Subjects: Brief intervention -- Primary care -- Motivational interviewing -- Risky drug use -- Randomized controlled trial -- Community health centers; Drug abuse -- Periodicals; Alcoholism -- Periodicals; 616.86
• DOI: 10.1016/j.drugalcdep.2017.04.022
• Languages: English
• ISSNs: 0376-8716

Abstract

Highlights: QUIT (Quit Using Drugs Intervention Trial) brief intervention reduced past month drug use by 4.5 days. QUIT protocol was efficacious in a variety of primary care settings. Screening for substance use could be implemented in federally qualified health centers (FQHCs). Abstract: Background: QUIT is the only primary care-based brief intervention that has previously shown efficacy for reducing risky drug use in the United States (Gelberg et al., 2015). This pilot study replicated the QUIT protocol in one of the five original QUIT clinics primarily serving Latinos. Design: Single-blind, two-arm, randomized controlled trial of patients enrolled from March-October 2013 with 3-month follow-up. Setting: Primary care waiting room of a federally qualified health center (FQHC) in East Los Angeles. Participants: Adult patients with risky drug use (4–26 on the computerized WHO ASSIST): 65 patients (32 intervention, 33 control); 51 (78%) completed follow-up; mean age 30.8 years; 59% male; 94% Latino. Interventions and measures: Intervention patients received: 1) brief (typically 3–4 minutes) clinician advice to quit/reduce their risky drug use, 2) video doctor message reinforcing the clinician's advice, 3) health education booklet, and 4) up to two 20–30 minute follow-up telephone drug use reduction coaching sessions. Control patients received usual care and cancer screening information. Primary outcome was reduction in number of days of drug use in past 30 days of the highest scoring drug (HSD) on the baseline ASSIST, from baseline to 3-month follow-up. Results: Controls reported unchanged HSD use between baseline and 3-month follow-up whereas Intervention patients reported reducing their use by 40% (p < 0.001). In an intent-to-treat linear regression analysis, intervention patients reduced past month HSD use by 4.5 more days than controls (p < 0.042, 95% CI: 0.2, 8.7). Similar significant results were found using a complete sample regression analysis: 5.2 days (p < 0.03, 95% CI: 0.5, 9.9). Additionally, on logistic regression analysis of test results from 47 urine samples at follow-up, intervention patients were less likely than controls to test HSD positive (p < 0.05; OR: 0.10, 95% CI: 0.01, 0.99). Conclusions: Findings support the efficacy of the QUIT brief intervention for reducing risky drug use.